Isoquercetin

Generic Name: Isoquercetin

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₀O_₁₂

CAS Number: 482-35-9

Unique Ingredient Identifier: 6HN2PC637T

Background: Isoquercetin has been used in trials studying the treatment of Kidney Cancer, Renal cell carcinoma, Advanced Renal Cell Carcinoma, Thromboembolism of Vein in Pancreatic Cancer, and Thromboembolism of Vein VTE in Colorectal Cancer, among others.

Clinical Trials

The Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer

Phase 3

Not yet recruiting

Conditions: Venous Thromboembolism
Metastatic Pancreatic Cancer

Interventions: Drug: Isoquercetin
Drug: Placebo

First Posted Date: 2025-03-06

Last Posted Date: 2025-03-06

Lead Sponsor: Quercis Pharma AG

Target Recruit Count: 340

Registration Number: NCT06861088

Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19

Phase 2

Conditions: Covid19

Interventions: Drug: Hospital standard of care for COVID-19
Drug: Isoquercetin

First Posted Date: 2021-02-02

Last Posted Date: 2021-02-05

Lead Sponsor: Nepal Health Research Council

Target Recruit Count: 250

Registration Number: NCT04733651

Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Phase 2

Recruiting

Conditions: COVID-19
Coronavirus Disease 2019
SARS-CoV 2

Interventions: Drug: Masitinib
Drug: Isoquercetin
Drug: Best Supportive Care

First Posted Date: 2020-11-10

Last Posted Date: 2023-02-06

Lead Sponsor: AB Science

Target Recruit Count: 200

Registration Number: NCT04622865

Locations: 🇫🇷
Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France
🇫🇷
CHU Clermont-Ferrand: Site Gabriel-Montpied, Clermont-Ferrand, France
🇫🇷
Le Tripode, Groupe hospitalier Pellegrin CHU de Bordeaux, Bordeaux, France

and more 3 locations

Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

Phase 2

Withdrawn

Conditions: COVID-19

Interventions: Drug: Isoquercetin (IQC-950AN)

First Posted Date: 2020-09-02

Last Posted Date: 2025-03-24

Lead Sponsor: Institut de Recherches Cliniques de Montreal

Target Recruit Count: 150

Registration Number: NCT04536090

Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Placebo
Drug: Isoquercetin

First Posted Date: 2020-08-17

Last Posted Date: 2024-01-02

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 46

Registration Number: NCT04514510

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Isoquercetin in Sickle Cell Anemia

Phase 2

Withdrawn

Conditions: Sickle Cell-Beta0-Thalassemia
Sickle Cell Disease

Interventions: Drug: Isoquercetin

First Posted Date: 2020-07-17

Last Posted Date: 2021-01-11

Lead Sponsor: Jeffrey Zwicker, MD

Registration Number: NCT04474626

Impact of isoQUercetin and Aspirin on Platelet Function

Not Applicable

Withdrawn

Conditions: Cardiovascular Disease

Interventions: Drug: Isoquercetin plus Aspirin
Drug: Vehicle control
Drug: Isoquercetin
Drug: Aspirin

First Posted Date: 2016-08-15

Last Posted Date: 2016-11-29

Lead Sponsor: University of Reading

Registration Number: NCT02866448

Locations: 🇬🇧
University of Reading, Reading, Berkshire, United Kingdom

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

Phase 1

Conditions: Kidney Cancer
Renal Cell Carcinoma

Interventions: Drug: Sunitinib
Drug: Placebo
Drug: Isoquercetin

First Posted Date: 2015-05-18

Last Posted Date: 2017-01-18

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 104

Registration Number: NCT02446795

Locations: 🇮🇹
Ospedale Oncologico Regionale - Centro di Riferimento Oncologico di Basilicata U.O. di Oncologia Medica, Rionero in vulture, Potenza, Italy
🇮🇹
Fondazione G. Pascale, Naples, Italy
🇮🇹
University Federico II of Naples, Naples, Italy

and more 2 locations

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

Phase 2

Completed

Conditions: Thromboembolism of Vein VTE in Colorectal Cancer
Thromboembolism of Vein in Non-small Cell Lung Cancer
Thromboembolism of Vein in Pancreatic Cancer

Interventions: Drug: Isoquercetin

First Posted Date: 2014-07-21

Last Posted Date: 2021-03-03

Lead Sponsor: Jeffrey Zwicker, MD

Target Recruit Count: 64

Registration Number: NCT02195232

Locations: 🇺🇸
York Hospital-Oncology Treatment Center, York, Maine, United States
🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
🇺🇸
Veterans Affair Medical Center, Washington, District of Columbia, United States

and more 8 locations

Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States

Early Phase 1

Completed

Conditions: Healthy

Interventions: Drug: isoquercetin or quercetin

First Posted Date: 2012-11-07

Last Posted Date: 2020-10-12

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 38

Registration Number: NCT01722669

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy